Renovaro (RENB) Competitors $0.81 -0.04 (-4.46%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RENB vs. MLYS, RNAC, ALT, MREO, PROK, ERAS, AKBA, KALV, ORGO, and ETONShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Mineralys Therapeutics (MLYS), Cartesian Therapeutics (RNAC), Altimmune (ALT), Mereo BioPharma Group (MREO), ProKidney (PROK), Erasca (ERAS), Akebia Therapeutics (AKBA), KalVista Pharmaceuticals (KALV), Organogenesis (ORGO), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Mineralys Therapeutics Cartesian Therapeutics Altimmune Mereo BioPharma Group ProKidney Erasca Akebia Therapeutics KalVista Pharmaceuticals Organogenesis Eton Pharmaceuticals Mineralys Therapeutics (NASDAQ:MLYS) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Do insiders and institutionals hold more shares of MLYS or RENB? 84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 21.7% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor MLYS or RENB? In the previous week, Renovaro had 1 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 2 mentions for Renovaro and 1 mentions for Mineralys Therapeutics. Renovaro's average media sentiment score of 0.91 beat Mineralys Therapeutics' score of 0.25 indicating that Renovaro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Renovaro 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer MLYS or RENB? Mineralys Therapeutics received 16 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformMineralys TherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesRenovaroN/AN/A Do analysts rate MLYS or RENB? Mineralys Therapeutics presently has a consensus price target of $27.00, suggesting a potential upside of 187.54%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, MLYS or RENB? Mineralys Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Which has better earnings & valuation, MLYS or RENB? Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.64-2.58RenovaroN/AN/A-$80.65M-$0.93-0.88 Is MLYS or RENB more profitable? Renovaro's return on equity of -56.82% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -67.97% -62.40% Renovaro N/A -56.82%-44.72% SummaryMineralys Therapeutics and Renovaro tied by winning 7 of the 14 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.15M$7.07B$5.80B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.886.0226.3218.88Price / SalesN/A316.05452.0876.91Price / CashN/A67.8344.0437.47Price / Book0.926.757.644.66Net Income-$80.65M$138.11M$3.18B$245.69M7 Day Performance1.37%-1.85%-1.66%-2.22%1 Month Performance14.70%-1.39%0.41%-1.95%1 Year Performance-61.32%-2.92%17.47%14.12% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro1.0996 of 5 stars$0.81-4.2%N/A-58.1%$128.72MN/A-0.8720Earnings ReportNews CoverageGap UpMLYSMineralys Therapeutics2.6397 of 5 stars$9.51-3.1%$30.00+215.5%-37.7%$473.31MN/A-2.9128RNACCartesian Therapeutics1.7565 of 5 stars$18.51+0.8%$42.86+131.5%-11.9%$470.43M$47.94M-0.3564ALTAltimmune2.6485 of 5 stars$6.61-0.8%$20.83+215.2%-21.1%$470.10M$430,000.00-4.2650Short Interest ↓MREOMereo BioPharma Group2.955 of 5 stars$3.02-2.9%$7.83+159.4%-19.8%$468.55M$10M0.0040PROKProKidney1.3648 of 5 stars$1.59+1.9%$4.50+183.0%+1.3%$463.74MN/A-2.893Gap UpERASErasca2.2021 of 5 stars$1.64+3.1%$5.70+247.6%-25.9%$463.68MN/A-1.98120Gap UpAKBAAkebia Therapeutics4.1251 of 5 stars$2.10-1.9%$7.50+257.1%+32.3%$458.18M$194.62M-9.13430Analyst DowngradeKALVKalVista Pharmaceuticals4.7412 of 5 stars$9.19-0.1%$23.80+159.0%-22.9%$454.15MN/A-2.52100Short Interest ↓News CoverageORGOOrganogenesis4.0237 of 5 stars$3.57+3.2%$5.00+40.1%-1.2%$448.86M$433.14M-59.50950News CoverageETONEton Pharmaceuticals2.9057 of 5 stars$17.16-3.1%$24.00+39.9%+230.0%$447.02M$31.64M-78.0020 Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives Cartesian Therapeutics Alternatives Altimmune Alternatives Mereo BioPharma Group Alternatives ProKidney Alternatives Erasca Alternatives Akebia Therapeutics Alternatives KalVista Pharmaceuticals Alternatives Organogenesis Alternatives Eton Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RENB) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RENB Stock Alerts